PMO and the PMC -- A Collaboration to Advance Precision Medicine.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 238
- Publication type:
- Article
Works matching IS 21660166 AND DT 2014 AND VI 3 AND IP 4
Results: 20
1
2
Highest Response Rate to Date With a Third-Line VEGF Inhibitor, Pazopanib, in Metastatic Renal Cell Carcinoma.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 236
- Publication type:
- Article
3
Potential New Approach to Treatment of Melanoma.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 235
- Publication type:
- Article
4
Simple Blood Test Predicts Response to Enzalutamide in Patients With Prostate Cancer.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 234
- Publication type:
- Article
5
FGFR Inhibitor Shows Promising Anticancer Activity.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 233
- Publication type:
- Article
6
PD-L1 Expression a Potential Biomarker for Response to Immunotherapy With MK-3475.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 232
- Publication type:
- Article
7
Multitargeted Kinase Inhibitor Shows Promising Results for Breast Cancer Subgroup.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 231
- Publication type:
- Article
8
CDK 4/6 Inhibitor Slows Progression of Metastatic Breast Cancer.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 230
- Publication type:
- Article
9
Prospects for Personalization of Medicine Lie in Evidence Thresholds.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 228
- Publication type:
- Article
10
PARP Inhibitor Active in Recurrent BRCA-Positive Ovarian Cancer.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 227
- Publication type:
- Article
11
New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 226
- Publication type:
- Article
12
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 224
- Publication type:
- Article
13
Phi Index Can Select Patients With Prostate Cancer for Active Surveillance.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 223
- Publication type:
- Article
14
Bevacizumab Improves Survival in Patients With Metastatic Colorectal Cancer.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 222
- Publication type:
- Article
15
Personalizing Value-Based Medicine.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 220
- By:
- Publication type:
- Article
16
Androgen Suppression in Castration-Resistant Prostate Cancer.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 212
- Publication type:
- Article
17
Implementing Global Healthcare: Partners In Health and the Rwandan Cancer Center Initiative.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 206
- Publication type:
- Article
18
Molecular Diversity of CLL.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 202
- Publication type:
- Article
19
Immuno-Oncology Takes Center Stage at ASCO 2014.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 198
- Publication type:
- Article
20
The Evolution of Personalized Medicine in Oncology.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 4, p. 196
- By:
- Publication type:
- Article